Название продукции:7-Bromo-4-chloro-1H-indazol-3-amine
IUPAC Name:7-bromo-4-chloro-1H-indazol-3-amine
- CAS：1626336-65-9
- Молекулярная формула：C7H5BrClN3
- Чистота：95%+
- Номер в каталоге：CM535920
- Молекулярная масса：246.49
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:1626336-65-9
- Молекулярная формула:C7H5BrClN3
- Точка плавления:-
- Smiles-код:NC1=NNC2=C1C(Cl)=CC=C2Br
- Плотность:
- Номер в каталоге:CM535920
- Молекулярная масса:246.49
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Indazoles
- Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.
Column Infos
- Islatravir and Lenacapavir
- Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Поиск 
+86 21 5895 0110 
